ICER suggests Novartis' MS therapy siponimod won't be cost-effective

ICER said the price of multiple sclerosis therapy Mayzent siponimod from Novartis would have to reach a monthly net price of $995 to meet its standard cost-effectiveness threshold of $150,000 per QALY. That price would be an 88% discount from the monthly wholesale acquisition cost (WAC) of $8,210 for the pharma's MS drug Gilenya fingolimod.

In a draft evidence report released Thursday, the Institute for Clinical and Economic Review estimated a price of $826,000 per quality-associated life year (QALY) for siponimod...